An Audit of Growth Hormone replacement for GH-deficient adults in Scotland

Sam Philip, Isobel Howat, Maggie Carson, Anne Booth, Karen Campbell, Donna Grant, Catherine Patterson, Christopher Schofield, John Bevan, Alan Patrick, Graham Leese, John Connell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVE: Guidelines on the clinical use of growth hormone therapy in adults adults were issued by the UK National Institute for Clinical Excellence (NICE) in August 2003. We conducted a retrospective clinical audit on the use of growth hormone (GH) in Scotland to evaluate the use of these guidelines and their impact on clinical practice. The audit had 2 phases. In Phase I, the impact of NICE criteria on specialist endocrine practice in starting and continuing GH replacement was assessed. In Phase II, the reasons why some adults in Scotland with growth hormone deficiency were not on replacement therapy were evaluated. METHODS: A retrospective cross-sectional case note review was carried out of all adult patients being followed up for growth hormone deficiency during the study period (1st March 2005 to 31st March 2008). Phase I of the audit included 208 patients and Phase II 108 patients. RESULTS: Sellar tumours were the main cause of GH deficiency in both phases of the audit. In Phase I, fifty-three patients (77%) had an AGHDA-QoL score >11 documented before commencing GH post-NICE guidance, compared with 35 (25%) pre-NICE guidance. Overall, only 39 patients (18%) met the full NICE criteria for starting and continuing GH (pre-NICE, 11%; post-NICE, 35%). Phase II indicated that the main reasons for not starting GH included perceived satisfactory quality of life (n=47, 43%), patient reluctance (16,15%) or a medical contraindication (16,15%). CONCLUSIONS: Although the use of quality of life assessments has increased following publication of the NICE guidelines, most adults on GH in Scotland did not fulfill the complete set of NICE criteria. The main reason for not starting GH therapy in adult GH-deficient patients was perceived satisfactory quality of life. © 2012 Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)571-576
Number of pages6
JournalClinical Endocrinology
Volume78
Issue number4
Early online date12 Mar 2013
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Scotland
Growth Hormone
Quality of Life
Guidelines
Clinical Audit
Publications
Therapeutics

Cite this

Philip, S., Howat, I., Carson, M., Booth, A., Campbell, K., Grant, D., ... Connell, J. (2013). An Audit of Growth Hormone replacement for GH-deficient adults in Scotland. Clinical Endocrinology, 78(4), 571-576. https://doi.org/10.1111/cen.12017

An Audit of Growth Hormone replacement for GH-deficient adults in Scotland. / Philip, Sam; Howat, Isobel; Carson, Maggie; Booth, Anne; Campbell, Karen; Grant, Donna; Patterson, Catherine; Schofield, Christopher; Bevan, John; Patrick, Alan; Leese, Graham; Connell, John.

In: Clinical Endocrinology, Vol. 78, No. 4, 04.2013, p. 571-576.

Research output: Contribution to journalArticle

Philip, S, Howat, I, Carson, M, Booth, A, Campbell, K, Grant, D, Patterson, C, Schofield, C, Bevan, J, Patrick, A, Leese, G & Connell, J 2013, 'An Audit of Growth Hormone replacement for GH-deficient adults in Scotland', Clinical Endocrinology, vol. 78, no. 4, pp. 571-576. https://doi.org/10.1111/cen.12017
Philip, Sam ; Howat, Isobel ; Carson, Maggie ; Booth, Anne ; Campbell, Karen ; Grant, Donna ; Patterson, Catherine ; Schofield, Christopher ; Bevan, John ; Patrick, Alan ; Leese, Graham ; Connell, John. / An Audit of Growth Hormone replacement for GH-deficient adults in Scotland. In: Clinical Endocrinology. 2013 ; Vol. 78, No. 4. pp. 571-576.
@article{83f5b229e4f54ca8a1b179c6b367fadd,
title = "An Audit of Growth Hormone replacement for GH-deficient adults in Scotland",
abstract = "OBJECTIVE: Guidelines on the clinical use of growth hormone therapy in adults adults were issued by the UK National Institute for Clinical Excellence (NICE) in August 2003. We conducted a retrospective clinical audit on the use of growth hormone (GH) in Scotland to evaluate the use of these guidelines and their impact on clinical practice. The audit had 2 phases. In Phase I, the impact of NICE criteria on specialist endocrine practice in starting and continuing GH replacement was assessed. In Phase II, the reasons why some adults in Scotland with growth hormone deficiency were not on replacement therapy were evaluated. METHODS: A retrospective cross-sectional case note review was carried out of all adult patients being followed up for growth hormone deficiency during the study period (1st March 2005 to 31st March 2008). Phase I of the audit included 208 patients and Phase II 108 patients. RESULTS: Sellar tumours were the main cause of GH deficiency in both phases of the audit. In Phase I, fifty-three patients (77{\%}) had an AGHDA-QoL score >11 documented before commencing GH post-NICE guidance, compared with 35 (25{\%}) pre-NICE guidance. Overall, only 39 patients (18{\%}) met the full NICE criteria for starting and continuing GH (pre-NICE, 11{\%}; post-NICE, 35{\%}). Phase II indicated that the main reasons for not starting GH included perceived satisfactory quality of life (n=47, 43{\%}), patient reluctance (16,15{\%}) or a medical contraindication (16,15{\%}). CONCLUSIONS: Although the use of quality of life assessments has increased following publication of the NICE guidelines, most adults on GH in Scotland did not fulfill the complete set of NICE criteria. The main reason for not starting GH therapy in adult GH-deficient patients was perceived satisfactory quality of life. {\circledC} 2012 Blackwell Publishing Ltd.",
author = "Sam Philip and Isobel Howat and Maggie Carson and Anne Booth and Karen Campbell and Donna Grant and Catherine Patterson and Christopher Schofield and John Bevan and Alan Patrick and Graham Leese and John Connell",
note = "{\circledC} 2012 Blackwell Publishing Ltd.",
year = "2013",
month = "4",
doi = "10.1111/cen.12017",
language = "English",
volume = "78",
pages = "571--576",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - An Audit of Growth Hormone replacement for GH-deficient adults in Scotland

AU - Philip, Sam

AU - Howat, Isobel

AU - Carson, Maggie

AU - Booth, Anne

AU - Campbell, Karen

AU - Grant, Donna

AU - Patterson, Catherine

AU - Schofield, Christopher

AU - Bevan, John

AU - Patrick, Alan

AU - Leese, Graham

AU - Connell, John

N1 - © 2012 Blackwell Publishing Ltd.

PY - 2013/4

Y1 - 2013/4

N2 - OBJECTIVE: Guidelines on the clinical use of growth hormone therapy in adults adults were issued by the UK National Institute for Clinical Excellence (NICE) in August 2003. We conducted a retrospective clinical audit on the use of growth hormone (GH) in Scotland to evaluate the use of these guidelines and their impact on clinical practice. The audit had 2 phases. In Phase I, the impact of NICE criteria on specialist endocrine practice in starting and continuing GH replacement was assessed. In Phase II, the reasons why some adults in Scotland with growth hormone deficiency were not on replacement therapy were evaluated. METHODS: A retrospective cross-sectional case note review was carried out of all adult patients being followed up for growth hormone deficiency during the study period (1st March 2005 to 31st March 2008). Phase I of the audit included 208 patients and Phase II 108 patients. RESULTS: Sellar tumours were the main cause of GH deficiency in both phases of the audit. In Phase I, fifty-three patients (77%) had an AGHDA-QoL score >11 documented before commencing GH post-NICE guidance, compared with 35 (25%) pre-NICE guidance. Overall, only 39 patients (18%) met the full NICE criteria for starting and continuing GH (pre-NICE, 11%; post-NICE, 35%). Phase II indicated that the main reasons for not starting GH included perceived satisfactory quality of life (n=47, 43%), patient reluctance (16,15%) or a medical contraindication (16,15%). CONCLUSIONS: Although the use of quality of life assessments has increased following publication of the NICE guidelines, most adults on GH in Scotland did not fulfill the complete set of NICE criteria. The main reason for not starting GH therapy in adult GH-deficient patients was perceived satisfactory quality of life. © 2012 Blackwell Publishing Ltd.

AB - OBJECTIVE: Guidelines on the clinical use of growth hormone therapy in adults adults were issued by the UK National Institute for Clinical Excellence (NICE) in August 2003. We conducted a retrospective clinical audit on the use of growth hormone (GH) in Scotland to evaluate the use of these guidelines and their impact on clinical practice. The audit had 2 phases. In Phase I, the impact of NICE criteria on specialist endocrine practice in starting and continuing GH replacement was assessed. In Phase II, the reasons why some adults in Scotland with growth hormone deficiency were not on replacement therapy were evaluated. METHODS: A retrospective cross-sectional case note review was carried out of all adult patients being followed up for growth hormone deficiency during the study period (1st March 2005 to 31st March 2008). Phase I of the audit included 208 patients and Phase II 108 patients. RESULTS: Sellar tumours were the main cause of GH deficiency in both phases of the audit. In Phase I, fifty-three patients (77%) had an AGHDA-QoL score >11 documented before commencing GH post-NICE guidance, compared with 35 (25%) pre-NICE guidance. Overall, only 39 patients (18%) met the full NICE criteria for starting and continuing GH (pre-NICE, 11%; post-NICE, 35%). Phase II indicated that the main reasons for not starting GH included perceived satisfactory quality of life (n=47, 43%), patient reluctance (16,15%) or a medical contraindication (16,15%). CONCLUSIONS: Although the use of quality of life assessments has increased following publication of the NICE guidelines, most adults on GH in Scotland did not fulfill the complete set of NICE criteria. The main reason for not starting GH therapy in adult GH-deficient patients was perceived satisfactory quality of life. © 2012 Blackwell Publishing Ltd.

U2 - 10.1111/cen.12017

DO - 10.1111/cen.12017

M3 - Article

C2 - 22901318

VL - 78

SP - 571

EP - 576

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 4

ER -